Skip to main content

Table 5 Patient characteristics by relapse

From: Vision loss in patients with giant cell arteritis treated with tocilizumab

  All No relapse Relapse p value
n (%) or median (IQ range) n (%) or median (IQ range) n (%) or median (IQ range)  
Total N N = 186 N = 119 N = 67  
Female 116 (62%) 77 (65%) 39 (58%) 0.432
Age at diagnosis 71.0 (63.0; 77.0) 71.0 (66.0; 77.0) 69.0 (62.0; 76.0) 0.174
Cranial symptoms (incl. visual imp.) 124 (67%) 81 (68%) 43 (64%) 0.629
Visual symptoms 70 (38%) 49 (41%) 21 (31%) 0.209
Vision loss 21 (11%) 15 (13%) 6 (9%) 0.630
Headache 93 (50%) 58 (49%) 35 (52%) 0.760
Jaw claudication 48 (26%) 33 (28%) 15 (22%) 0.487
Scalp tenderness 42 (23%) 23 (19%) 19 (28%) 0.201
Claudication of tongue 2 (1%) 2 (2%) 0 (0%) 0.537
Fever ≥ 38 °C 35 (19%) 20 (17%) 15 (22%) 0.435
Weight loss > 2 kg within 4 weeks 50 (27%) 29 (24%) 21 (31%) 0.389
Night sweat 33 (18%) 22 (18%) 11 (16%) 0.843
Polymyalgia rheumatica 90 (48%) 58 (49%) 32 (48%) 0.878